Turn Therapeutics Inc Financials
This page shows Turn Therapeutics Inc (TTRX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 2 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Turn Therapeutics is in an externally financed balance-sheet build, with cash rising through financing while operations still absorb cash.
Cash reached$4.0M in FY2025 from$498K a year earlier. That improvement came while operating cash flow remained negative at-$2.6M and was enabled by$6.9M of financing inflows, so the higher cash balance reflects a funding event rather than self-funded operations.
The capital structure changed materially: equity moved from
The cost base is overwhelmingly SG&A-led: selling and administrative expense was
Financial Health Signals
Turn Therapeutics Inc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Turn Therapeutics Inc passes 2 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
Turn Therapeutics Inc reported a net loss of $3.2M while operations used $2.6M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Turn Therapeutics Inc's EBITDA was -$5.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 231.8% from the prior year.
Turn Therapeutics Inc reported -$3.2M in net income in fiscal year 2025. This represents a decrease of 80.6% from the prior year.
Turn Therapeutics Inc earned -$0.12 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 71.4% from the prior year.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Turn Therapeutics Inc held $4.0M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Turn Therapeutics Inc's ROE was -68.2% in fiscal year 2025, measuring profit generated per dollar of shareholder equity.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Capital Allocation
Turn Therapeutics Inc invested $266K in research and development in fiscal year 2025. This represents an increase of 8.0% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
TTRX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 |
|---|---|---|---|
| R&D Expenses | N/A | $266K+8.0% | $246K |
| SG&A Expenses | N/A | $5.6M+260.6% | $1.6M |
| Operating Income | N/A | -$5.9M-226.0% | -$1.8M |
| Net Income | N/A | -$3.2M-80.6% | -$1.8M |
| EPS (Diluted) | — | -$0.12-71.4% | -$0.07 |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Interest Expense, Income Tax.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
TTRX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 |
|---|---|---|
| Total Assets | $12.2M+493.6% | $2.0M |
| Current Assets | $5.2M+373.3% | $1.1M |
| Cash & Equivalents | $4.0M+708.3% | $498K |
| Total Liabilities | $7.5M+235.8% | $2.2M |
| Current Liabilities | $6.0M+748.0% | $708K |
| Total Equity | $4.7M+2741.4% | -$177K |
| Retained Earnings | -$22.4M-16.6% | -$19.2M |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
TTRX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 |
|---|---|---|---|
| Operating Cash Flow | -$4.3M | -$2.6M-88.3% | -$1.4M |
| Investing Cash Flow | -$139K | -$153K-53.8% | -$99K |
| Financing Cash Flow | $11.6M | $6.9M+500.4% | $1.2M |
Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
TTRX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 |
|---|---|---|
| Return on Equity | -68.2% | N/A |
| Return on Assets | -26.3%+60.1pp | -86.3% |
| Current Ratio | 0.87-0.7x | 1.55 |
| Debt-to-Equity | 1.59 | N/A |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, FCF Margin.
Note: The current ratio is below 1.0 (0.87), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Where Turn Therapeutics Inc Ranks
Frequently Asked Questions
Is Turn Therapeutics Inc profitable?
No, Turn Therapeutics Inc (TTRX) reported a net income of -$3.2M in fiscal year 2025.
What is Turn Therapeutics Inc's EBITDA?
Turn Therapeutics Inc (TTRX) had EBITDA of -$5.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Turn Therapeutics Inc's return on equity (ROE)?
Turn Therapeutics Inc (TTRX) has a return on equity of -68.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Turn Therapeutics Inc's operating cash flow?
Turn Therapeutics Inc (TTRX) recorded an outflow of $2.6M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Turn Therapeutics Inc's total assets?
Turn Therapeutics Inc (TTRX) had $12.2M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Turn Therapeutics Inc spend on research and development?
Turn Therapeutics Inc (TTRX) invested $266K in research and development during fiscal year 2025.
What is Turn Therapeutics Inc's current ratio?
Turn Therapeutics Inc (TTRX) had a current ratio of 0.87 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is Turn Therapeutics Inc's debt-to-equity ratio?
Turn Therapeutics Inc (TTRX) had a debt-to-equity ratio of 1.59 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Turn Therapeutics Inc's return on assets (ROA)?
Turn Therapeutics Inc (TTRX) had a return on assets of -26.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Turn Therapeutics Inc's cash runway?
Based on fiscal year 2025 data, Turn Therapeutics Inc (TTRX) had $4.0M in cash against an annual operating cash burn of $2.6M. This gives an estimated cash runway of approximately 19 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Turn Therapeutics Inc's Piotroski F-Score?
Turn Therapeutics Inc (TTRX) has a Piotroski F-Score of 2 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Turn Therapeutics Inc's earnings high quality?
Turn Therapeutics Inc (TTRX) reported a net loss of $3.2M while operations used $2.6M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.